NYSTATIN-TRIAMCINOLONE ACETONIDE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Nystatin is not significantly absorbed through intact skin or mucous membranes; systemic metabolism is negligible. Triamcinolone acetonide is metabolized primarily in the liver via CYP3A4 to 6β-hydroxytriamcinolone and other metabolites. |
| Excretion | Nystatin: negligible systemic absorption; excreted unchanged in feces (~100%). Triamcinolone acetonide: metabolized hepatically; renal excretion of metabolites (~40%) and unchanged drug (<5%); fecal excretion (~60%). |
| Half-life | Nystatin: negligible systemic half-life due to lack of absorption. Triamcinolone acetonide: terminal half-life ~2-5 hours (mean ~3.5 h) after intravascular administration; prolonged in hepatic impairment. |
| Protein binding | Nystatin: negligible binding (not absorbed). Triamcinolone acetonide: ~68% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Nystatin: not applicable (no systemic distribution). Triamcinolone acetonide: Vd ~1.2 L/kg (0.8-1.5 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Nystatin: essentially 0% oral/nasal (not absorbed); topical/vaginal: minimal systemic absorption. Triamcinolone acetonide: topical: <1% systemic absorption through intact skin; intramuscular: ~100% after injection. |
| Onset of Action | Nystatin: local effects on Candida begin within 24-72 hours of topical/ vaginal/oral application. Triamcinolone acetonide: topical anti-inflammatory effects noticeable within 2-3 days; intramuscular (systemic) onset within 24 hours. |
| Duration of Action | Nystatin: clinical effect persists during continued application; no systemic duration. Triamcinolone acetonide: topical duration 2-4 weeks after cessation due to depot in skin; intramuscular effects last 2-3 weeks due to slow release from injection site. |
Apply topically to affected area twice daily for 2-4 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for topical use; systemic absorption is negligible. |
| Liver impairment | No dosage adjustment required for topical use; systemic absorption is negligible. |
| Pediatric use | Apply sparingly to affected area twice daily; use for shortest duration necessary. Not recommended for children under 2 years unless directed by physician. |
| Geriatric use | Use with caution due to increased risk of skin atrophy and systemic effects from prolonged use; apply sparingly and for shortest duration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Breastfeeding | No human data on M/P ratio. Triamcinolone acetonide is excreted in breast milk in low amounts; nystatin is not absorbed orally and is unlikely to reach infant. Use caution with topical application to nipple/areola; avoid systemic absorption. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Hyperglycemia |
| Serious Effects |
["Hypersensitivity to nystatin, triamcinolone acetonide, or any component of the formulation","Viral infections of the skin (e.g., herpes simplex, varicella, vaccinia)","Untreated bacterial or fungal infections not caused by candidal species","Application to the eyes, mouth, or vaginal area (intravaginal use not indicated)"]
| Precautions | ["Prolonged use may lead to topical corticosteroid side effects including skin atrophy, striae, telangiectasias, and systemic absorption with hypothalamic-pituitary-adrenal (HPA) axis suppression, especially in children, on large areas, or under occlusion","If irritation or sensitization occurs, discontinue use","Do not use in the presence of untreated bacterial, viral, or fungal infections other than candidiasis","Avoid prolonged application to the face, groin, axillae, and intertriginous areas due to increased absorption","Use caution in patients with impaired immune response"] |
Loading safety data…
| Animal studies with triamcinolone acetonide have shown teratogenicity; corticosteroids are associated with increased risk of cleft palate and intrauterine growth restriction. Nystatin is not absorbed systemically and is considered low risk. First trimester: avoid systemic absorption; use only if benefit outweighs risk. Second/third trimester: avoid prolonged use due to potential fetal adrenal suppression. |
| Fetal Monitoring | Monitor fetal growth via ultrasound due to potential IUGR with prolonged corticosteroid use. Assess maternal adrenal function if used extensively. Monitor infant for signs of adrenal suppression if maternal use was prolonged/high-dose. |
| Fertility Effects | No known effect of nystatin on fertility. Triamcinolone acetonide may impair fertility in animal studies via hormonal disruption; human data limited. |